Loading...
•
Mar 31, 2022
Vaxcyte Q1 2022 Earnings Report
Vaxcyte reported financial results for the first quarter ended March 31, 2022 and provided a business update.
Key Takeaways
Vaxcyte reported cash, cash equivalents and investments of $352.3 million as of March 31, 2022. The company's net loss was $39.0 million for the three months ended March 31, 2022.
Dosed First Participants in both the Phase 1 and Phase 2 Portions of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
Completed Successful $115 Million Follow-On Financing
Appointed Mikhail Eydelman as Senior Vice President, General Counsel & Corporate Secretary
Vaxcyte expects to announce topline safety, tolerability and immunogenicity results from both the Phase 1 and Phase 2 portions of the Phase 1/2 clinical study evaluating VAX-24 for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults by the end of 2022.
Vaxcyte
Vaxcyte
Forward Guidance
Vaxcyte anticipates several key milestones for its vaccine candidates.
Positive Outlook
- Topline safety, tolerability and immunogenicity results from both the Phase 1 and Phase 2 portions of the Phase 1/2 clinical study evaluating VAX-24 for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults by the end of 2022.
- Enrollment in a separate Phase 2 study of approximately 200 healthy adults aged 65 and older in mid-2022 to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-24.
- Topline results from the Phase 2 study in adults aged 65 and older are expected to be announced in the first half of 2023.
- Submission of its first VAX-24 pediatric Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the first half of 2023.
- Guidance for the anticipated submission of its IND application in adults to the FDA following the announcement of the topline results from the ongoing VAX-24 Phase 1/2 study in adults aged 18 to 64 for VAX-XP.